Artificial intelligence, intra-entrepreneurship and big data were some of the key topics of the ` I National Forum on Innovation Management in Healthcare
The Marqués de Valdecilla Health Research Institute (IDIVAL) together with the Ministry of Health of the Government of Cantabria organized on April 28 the 1st National Forum on Innovation Management in Healthcare `MIND THE GAP’ which was attended by around 200 people from all over Spain and was sponsored by Janssen and supported by the Botín Foundation and the ITEMAS Platform.
The aim of this conference, which was open to companies, innovation and research managers, clinicians, managers and executives, was to discuss organizational innovation, focused on patients, knowledge and healthcare technologies. Artificial intelligence, intrapreneurship, big data or innovative public procurement were some of the key topics that were discussed in round table format at the Botín Foundation in Santander.
The coordinators of this meeting have valued this conference “as an excellent opportunity to establish synergies and collaborations between the different agents in the health innovation management environment, which aims to consolidate itself as a national reference forum”.
The conference was inaugurated by the Minister of Health, Raúl Pesquera, the Deputy Director General of Networks and Corporate Research Centers of the Carlos III Health Institute, Agustín González, and Ana Isabel Gil, representing the patients.
Also, the master conference ‘Precision Medicine, new realities, new challenges’ was given by Dr. Ángel Carracedo, director of the Foundation of Xenomic Medicine-SERGAS and Professor of Legal Medicine at the University of Santiago.
Los ponentes de esta jornada forman parte del Máster en Dirección y Gestión de la Innovación en Salud (MINDS) coordinado por IDIVAL y la Universidad Nebrija y que tiene como objetivo generar una red de profesionales del ámbito sanitario y de la empresa que puedan promover el desarrollo de la innovación en salud en su entorno.
The speakers at this conference are part of the Master in Management and Administration of Innovation in Healthcare (MINDS) coordinated by IDIVAL and Nebrija University, which aims to create a network of professionals from the healthcare and business fields who can promote the development of innovation in healthcare in their environment.
Registration open for the II Edition of the Master in Management and Management of Innovation in Health (MINDS)
IDIVAL and Nebrija University have opened registration for the second edition of the Master’s program, which is once again sponsored by Janssen and supported by the Botín Foundation. Those interested may also apply for one of the available tuition scholarships.
Through meetings with expert speakers from the fields of research, health, management and entrepreneurship, who will give a practical vision of their field, the participating students will acquire knowledge for the analysis, understanding, development and leadership of innovative projects in the public and private sectors. For this reason, both the faculty and the participating students have an interdisciplinary profile from teaching, management, technical or clinical fields.
Visits to the main innovation centers in the country and specific events will complement the program in order to learn first-hand about the management and progress of innovation.
With a hybrid format, online and face-to-face at the Botín Foundation in Madrid, the sessions will begin in September 2023 and will last until June 2024, during which the different works elaborated by the students will be presented.
Additional information on registration, programming and available scholarships can be found on the mindsmaster.org website or by contacting minds@idival.org.
Artificial intelligence, intra-entrepreneurship and big data were some of the key topics of the ` I National Forum on Innovation Management in Healthcare The Marqués de Valdecilla Health Research Institute (IDIVAL) together with the Ministry of Health of the Government of Cantabria organized on April 28 the 1st National Forum on Innovation Management in Healthcare […]
The Council of Ministers has approved this Wednesday the call 2023 of the ATRAE program specifically aimed at attracting R4 researchers, the highest echelon of a consolidated scientific career, to our universities and public research organizations.
This program will serve to hire a minimum of 25 PhDs with more than seven years of postdoctoral experience to develop their line of research in Spain. This call contemplates the possibility of increasing the endowment by 5 million more, up to 30 million, if the budget is available.
Research personnel eligible for these grants must have more than seven years of postdoctoral experience and have carried out their activity abroad for at least 5 of the last 7 years. The beneficiary research leaders will receive a grant of up to one million euros to develop their line of research in Spain.
This investment will serve to make our country and our public funding system more competitive to pay the salary of these researchers -which will be a minimum of 80,000 euros per year-, to hire the necessary research personnel to form their research group and for the acquisition of equipment and adaptation of spaces for the establishment of their group.
The aid will be requested by the researcher, who must have a letter of acceptance from the organization he/she intends to join and a commitment of consolidation. The contract will be for an initial duration of three to four years and the beneficiary will be the host institution.
The Council of Ministers has approved this Wednesday the call 2023 of the ATRAE program specifically aimed at attracting R4 researchers, the highest echelon of a consolidated scientific career, to our universities and public research organizations. This program will serve to hire a minimum of 25 PhDs with more than seven years of postdoctoral experience […]
Francisco Sánchez Madrid, member of IDIVAL’s External Council and Head of the Immunology Service of the Hospital Universitario de La Princesa has received the Robert Koch Award 2023. The immunologist and professor at Harvard University in Boston, Timothy Springer, has also been awarded this prize for their important joint research in Immunology.
Both were pioneers in discovering the relevance of cell adhesion molecules in immune cell function. This important finding has opened up new possibilities for the treatment of immune diseases using monoclonal antibodies.
The Robert Koch Prize is endowed with 120,000 euros, is considered one of the most important scientific prizes in Germany, and is awarded annually by the Robert Koch Foundation and the German Ministry of Health.
The Robert Koch Award ceremony will take place on November 17, 2023 in the city of Berlin. Francisco Sánchez Madrid and Timothy Springer will receive the award from the Nobel Laureate in Medicine, Professor Jules Hoffmann.
Alongside Professors Francisco Sánchez Madrid and Timothy Springer, Professor Patrice Courvalin, one of the world’s most renowned researchers in the field of antibiotic resistance, will receive the Robert Koch Gold Medal.
Francisco Sánchez Madrid
He is head of the Immunology Service of the Hospital Universitario de La Princesa, director of the Instituto de Investigación Sanitaria IIS Princesa, Professor of Immunology at the Universidad Autónoma de Madrid and member of the IDIVAL External Council that provides scientific advice to the Institute and is composed of people in the field of health sciences of recognized prestige in the scientific community. In addition, Professor Francisco Sánchez Madrid is also currently the director of the Intercellular Communication in the Inflammatory Response group at the National Center for Cardiovascular Research (CNIC).
Dr. Sánchez obtained his PhD from the Universidad Autónoma de Madrid in 1980. After his doctoral thesis, he moved to the Department of Pathology at Harvard Medical School in Boston, Massachusetts. It was then that, together with Professor Timothy Springer, they identified the integrins that control the adhesion and activation of leukocytes and thus made a decisive contribution to the development of therapies for inflammatory and autoimmune diseases, such as multiple sclerosis and Crohn’s disease.
Their subsequent research has made a decisive contribution to understanding the function of immune synapses, i.e. the structures by which immune cells communicate with each other or with other cells. This work is instrumental in unraveling the immune system and its role in the immune response in health and disease.
Francisco Sánchez Madrid, member of IDIVAL’s External Council and Head of the Immunology Service of the Hospital Universitario de La Princesa has received the Robert Koch Award 2023. The immunologist and professor at Harvard University in Boston, Timothy Springer, has also been awarded this prize for their important joint research in Immunology. Both were pioneers […]
A program in which new researchers from the health sector in Cantabria present the progress of their research.
On May 10 we will have the presentations of Camilo Palazuelos Calderón and Amaya Llorente Mecieces, within the Progress Reports Valdecilla program. The session will be held in the Innovation and User Experience Laboratory – Linnux at 14:00 hours, being broadcast live through the Zoom platform.
The ARCEUS project: Artificial intelligence for the early detection of intra-abdominal infection after colorectal surgery.
SPEAKER: Camilo Palazuelos Calderón
Camilo Palazuelos is Assistant Professor (Languages and Computer Systems area) at the Department of Mathematics, Statistics and Computer Science of the University of Cantabria. He holds a PhD in Science and Technology (2019), a master’s degree in Mathematics and Computer Science (2013) and an engineering degree in Computer Science (2012) from the University of Cantabria. He has visited several European research groups, such as the Distributed Sensor Systems Group (Philips Research Europe), the Oxford Centre for Industrial and Applied Mathematics (University of Oxford) and the Biomarkers and Susceptibility Unit (Catalan Institute of Oncology). His research focuses on the representation of knowledge with uncertainty and its integration and impact on clinical decision making, especially in surgery. He is the principal investigator of the regional ARCEUS project, which aims to develop an intelligent system capable of early and safe discharge of colorectal surgery patients. Camilo has published more than 30 journal articles, book chapters and conference contributions and has participated in national and international research projects.
Role of BCMA in Multiple Myeloma: mechanisms and drug resistance
SPEAKER: Amaya Llorente Mecieces
Amaya Llorente has a degree in Biochemistry from the University of Castilla La Mancha and a Master in Neurosciences from the University of Salamanca. In 2022 she joined the group of hematological neoplasms and hematopoietic progenitor transplantation to perform her doctoral thesis. During this year she has worked on the study of Multiple Myeloma, specifically the role of BCMA and its implication in the biology and treatments of this disease, under the supervision of Dr. Patricia Maiso Castellanos and Dr. Enrique María Ocio.
The session will be given in hybrid format, in person at the Linnux laboratory (free entrance until full capacity is reached) and online through the Zoom platform. To attend the virtual session, it is necessary to register through the following access link:
https://us06web.zoom.us/meeting/register/tZcsc-usrzktHNBA5kBmxBgurfKHZgv_u7Eu
The session will start at 14:00h. Each speaker’s talk will last about 20 minutes followed by a short discussion and agape.
If you have any questions or doubts, please contact proyectos1@idival.org and gesval4@idival.org
A program in which new researchers from the health sector in Cantabria present the progress of their research. On May 10 we will have the presentations of Camilo Palazuelos Calderón and Amaya Llorente Mecieces, within the Progress Reports Valdecilla program. The session will be held in the Innovation and User Experience Laboratory – Linnux at […]
These donations are destined to study Alzheimer’s markers to detect people at high risk of suffering from this disease in the future.
IDIVAL has received one more year the visit of Oscar Negrete and Fernando Cerro from the association ‘Unidos por un Reto’ to make a donation of 800€ that will be destined to Alzheimer’s research. This amount comes from the proceeds of the VII Night Trail and the IX Night Walk organized by this association, held in Cicero on April 7, 2023 and in which more than 700 people participated.
“An initiative with immense value”, as highlighted by Eloy Rodriguez, head of the Cognitive Impairment Unit of the Marqués de Valdecilla University Hospital (HUMV) and Galo Peralta, Director of Management of IDIVAL, who collected the donation. They both highlighted the importance of this type of projects that combine sport, research and solidarity, that raise awareness in society of health research and that contribute to promote the work of research personnel.
The donation will contribute to continue the study, led by Dr. Eloy Rodriguez, focused on detecting people at high risk of developing Alzheimer’s disease in the future. So far, the `Cohorte Valdecilla’ group has investigated the validity of two plasma markers called beta-amyloid 1-42 and p-tau181 and in the coming months another marker called NfL will be included.
Dr. Eloy Rodriguez explains that they intend “to study how these plasma markers relate to the current reference. If the correlation is good, they will try to determine cut-off points for the general population and thus be able to use them in the future to detect these people at risk by means of a blood test instead of a lumbar puncture”.
Association involved in the research
United for a Challenge’ is an association promoted by Óscar Negrete, a cycling enthusiast since childhood, who has not stopped pedaling and breaking records to raise money for a charitable cause: “to investigate the causes of Alzheimer’s disease”.
Since his father was diagnosed with this disease, Oscar has wanted to pay tribute to the man who was his mentor both in cycling and in his life. Therefore, through the initiative ‘United for a challenge’, he collaborates continuously with the IDIVAL Foundation supporting research in this area.
These donations are destined to study Alzheimer’s markers to detect people at high risk of suffering from this disease in the future. IDIVAL has received one more year the visit of Oscar Negrete and Fernando Cerro from the association ‘Unidos por un Reto’ to make a donation of 800€ that will be destined to Alzheimer’s […]
A forum organized by IDIVAL and given by world renowned experts who will present advances in the field of rare diseases.
The next module of the International Forum on Precision Medicine will begin next Monday, May 8, and will review the different lines of research in the field of rare diseases.
A forum mainly focused on the review of some of the methods of analysis and functional validation of genetic variants, personalized advances, therapeutic targets in the treatment of these diseases, and national and international organizational strategies aimed at a more accurate and individualized diagnosis of these diseases. This program aims to update this acquired knowledge, thanks to top level speakers, leaders in their respective fields, both nationally and internationally.
The program is coordinated by Dr. José A. Riancho Moral, Head of Section of the Internal Medicine Department of the Marqués de Valdecilla University Hospital and endorsed by the ITEMAS Platform, the Spanish Society of Clinical Pharmacology, the Biobanks and Biomodels Platform of the Carlos III Health Institute and the CIBERER.
A meeting aimed at clinical, research and support staff who wish to learn from experts about aspects related to research and precision medicine in the field of rare diseases in adults.
The course, taught in online format, will be held from May 8 to 17 from Monday to Thursday from 16:00 to 18:00 hours.
It is pending accreditation by the Commission for Continuing Education of healthcare professionals. A diploma will be provided to all attendees who meet 80% attendance.
Registration link: https://us06web.zoom.us/meeting/register/tZwkdu2pqz4vHdBCLd-BYOBUJJ22mJVmaZt1
A forum organized by IDIVAL and given by world renowned experts who will present advances in the field of rare diseases. The next module of the International Forum on Precision Medicine will begin next Monday, May 8, and will review the different lines of research in the field of rare diseases. A forum mainly […]
The results open the possibility of using 5 genes identified as markers that correlate with the severity of the disease in the brain.
The `Neurodegenerative Diseases´ group of the Marqués de Valdecilla Health Research Institute (IDIVAL) led by Dr. Jon Infante Ceberio has participated in a european multicenter study with the aim of identifying genes with relevant changes in the progression of the rare neurodegenerative disease called autosomal dominant cerebellar ataxia (SCA3), also known as Azores disease, Machado disease or Machado-Joseph disease.
The research reveals a set of 5 genes that undergo important changes in their expression in stages prior to the clinical development of the disease and correlate with its severity. These results open up the possibility of using these genes as markers for early detection of this disorder, monitoring its progression and analyzing how it responds to treatments.
Today there are no specific treatments to slow or halt the progression of SCA3, but rather care is focused on combating movement-related symptoms that affect motor coordination and balance. Therefore, the identification of accurate, reliable and easily accessible biomarkers is one of the necessary requirements for the development of clinical trials with the greatest guarantee of success.
In the study, published in the journal Brain, a blood analysis of the RNA molecules present or transcriptome was carried out in a group of patients with SCA3 at different evolutionary stages of the disease and in control subjects. Similarly, these analyses were performed on brain samples and the set of candidate genes obtained was replicated in an independent sample of SCA3 patients and healthy controls.
Finally, a set of 5 genes were identified in blood and brain that undergo important changes in their expression in presymptomatic stages of the disease and correlate with the severity of ataxia, which will have to be confirmed in future studies in order to be applied to the clinic.
Participation in consortia and networks
The responsible research group is also part of the Centers, Services and Reference Units (CSUR) of Hereditary Ataxias and Paraplegias of the Marqués de Valdecilla University Hospital (HUMV) accredited by the National Health System (NHS), as well as of the European Network of Rare Neurological Diseases (ERN-RND). Likewise, for more than two decades, they have been integrated in a european consortium that seeks to define the natural history of autosomal dominant cerebellar ataxias, as well as to build cohorts prepared for the implementation of clinical trials.
Several european projects (EUROSCA, RISCA, ESMI) have been funded in the framework of this consortium with the participation of HUMV and IDIVAL. The current project is part of the European Spinocerebellar ataxia type3/Machado-Joseph disease initiative (ESMI), EU Joint Programme – Neurodegenerative Disease Research (JPND).
The results open the possibility of using 5 genes identified as markers that correlate with the severity of the disease in the brain. The `Neurodegenerative Diseases´ group of the Marqués de Valdecilla Health Research Institute (IDIVAL) led by Dr. Jon Infante Ceberio has participated in a european multicenter study with the aim of identifying genes […]
